• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 21, 2020 at 11:52: PM
via Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”

article source
 




Top Bottom
Back
Quote